35,145 Shares in Caris Life Sciences, Inc. $CAI Purchased by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio purchased a new stake in Caris Life Sciences, Inc. (NASDAQ:CAI) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 35,145 shares of the company’s stock, valued at approximately $626,000.

Several other large investors also recently made changes to their positions in the business. Global Retirement Partners LLC grew its stake in shares of Caris Life Sciences by 99,900.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after purchasing an additional 999 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Caris Life Sciences by 839.4% in the first quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock worth $29,000 after buying an additional 1,469 shares during the last quarter. Fifth Third Bancorp acquired a new position in Caris Life Sciences in the first quarter worth approximately $31,000. Sterling Capital Management LLC lifted its position in shares of Caris Life Sciences by 128.3% during the 1st quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock valued at $34,000 after acquiring an additional 1,083 shares during the last quarter. Finally, Trifecta Capital Advisors LLC bought a new stake in shares of Caris Life Sciences during the 2nd quarter worth $37,000.

Caris Life Sciences Price Performance

Shares of NASDAQ:CAI opened at $24.03 on Thursday. The company’s fifty day moving average is $20.36 and its two-hundred day moving average is $18.91. The company has a market cap of $6.79 billion, a P/E ratio of 66.75 and a beta of 1.10. Caris Life Sciences, Inc. has a 12-month low of $14.19 and a 12-month high of $35.20. The company has a quick ratio of 4.88, a current ratio of 5.53 and a debt-to-equity ratio of 0.66.

Caris Life Sciences declared that its board has authorized a stock buyback plan on Monday, June 8th that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 2.1% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling at Caris Life Sciences

In related news, President David Spetzler sold 478,000 shares of the company’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $24.86, for a total transaction of $11,883,080.00. Following the transaction, the president directly owned 1,052,083 shares of the company’s stock, valued at approximately $26,154,783.38. The trade was a 31.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 50.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Weiss Ratings raised Caris Life Sciences from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, August 21st. UBS Group assumed coverage on Caris Life Sciences in a research note on Wednesday. They issued a “neutral” rating and a $28.00 price target on the stock. Wall Street Zen upgraded Caris Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. BTIG Research upped their price objective on shares of Caris Life Sciences from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Wolfe Research cut shares of Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. Seven research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $26.50.

Caris Life Sciences Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.